Business Context and Reporting Period
Company: Glaukos Corporation (GKOS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2024
Business Overview: Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing dropless platform therapies for glaucoma, corneal disorders, and retinal diseases. Key products include the iStent family of Micro-Invasive Glaucoma Surgery (MIGS) devices, Photrexa for keratoconus, and the recently commercialized iDose TR procedural pharmaceutical.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Net Sales | $96,670 | $78,048 | $277,982 | $232,346 |
| Gross Profit | $74,086 | $59,538 | $212,590 | $175,662 |
| Gross Margin | 77% | 76% | 76% | 76% |
| Operating Expenses | $98,746 | $87,548 | $306,290 | $265,740 |
| Loss from Operations | $(24,660) | $(28,010) | $(93,700) | $(90,078) |
| Net Loss | $(21,409) | $(30,444) | $(112,792) | $(97,882) |
| Diluted Net Loss Per Share | $(0.39) | $(0.63) | $(2.18) | $(2.03) |
| Cash & Equivalents | $100,143 | $93,467 | (Balance Sheet Data) | |
| Short-term Investments | $162,330 | $201,964 | ||
| Total Current Assets | $397,282 | $395,461 | (Balance Sheet Data) | |
| Total Current Liabilities | $71,684 | $74,014 | ||
| Convertible Senior Notes (Carrying) | $56,759 | $282,773 | (Balance Sheet Data) | |
| Accumulated Deficit | $(711,859) | $(599,067) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 24% in Q3 2024 and 20% for the nine months ended September 30, 2024, compared to the prior year. Growth was driven by the introduction of iDose TR and higher volumes of iStent family products, particularly iStent infinite.
- Debt Reduction: In June 2024, the Company exchanged $230.0 million of its 2.75% Convertible Senior Notes for common stock. This reduced the carrying value of convertible notes on the balance sheet from $282.8 million (Dec 31, 2023) to $56.8 million (Sep 30, 2024).
- Non-Operating Charges: The nine-month 2024 results included a non-cash inducement charge of $17.4 million and transaction costs of $0.6 million related to the convertible note exchange, significantly impacting the net loss for the period.
- Acquisitions: The Company incurred $14.2 million in acquired in-process research and development (IPR&D) expenses for the nine months ended September 30, 2024, compared to $3.0 million in the prior year period, due to asset acquisitions and license agreements.
- Working Capital: Accounts receivable increased by $16.5 million and inventory increased by $18.2 million during the nine months ended September 30, 2024, reflecting business growth and preparation for product demand.
Guidance, Outlook, and Risks
- Convertible Note Redemption: On October 4, 2024, the Company issued a notice of redemption for the remaining $57.5 million aggregate principal amount of its Convertible Notes. The redemption date is December 16, 2024. Holders may convert notes into common stock prior to this date.
- Product Outlook: The Company continues to commercialize iDose TR in a controlled manner. Management notes that CMS physician fee payment rate decreases have disrupted traditional ordering patterns for iStent products used with cataract surgery, potentially reducing volumes.
- Reimbursement Environment: Five of seven Medicare Administrative Contractors (MACs) finalized draft Local Coverage Determinations (LCDs) in October 2024 confirming coverage for standalone iStent infinite procedures but non-coverage for surgical MIGS procedures in combination with other glaucoma procedures. These take effect November 17, 2024.
- Risk Factors:
- Commercialization Risk: Failure to achieve commercial success with iDose TR could materially impact the business.
- Supply Chain: Disruptions in manufacturing or supply of principal products could reduce gross margins.
- Profitability: The Company has an accumulated deficit of $711.9 million and may not reach sustained profitability.
- Regulatory: Changes in healthcare legislation, reimbursement rates, or regulatory approvals could hinder commercial success.
Investor Verification Checklist
- Debt Status: Verify the final settlement of the $57.5 million Convertible Notes redemption scheduled for December 16, 2024, and the extent of any conversion to equity.
- iDose TR Adoption: Monitor sales volumes and reimbursement rates for iDose TR following the assignment of permanent J-code (J7355) and CPT codes.
- Reimbursement Impact: Assess the financial impact of the finalized MAC LCDs effective November 17, 2024, on iStent infinite standalone procedure volumes.
- Cash Burn: Review the trajectory of operating cash burn ($61.8 million used in operating activities for 9M 2024) against current cash and investment balances ($262.5 million) to determine runway.
- Acquisition Milestones: Track potential future milestone payments (up to $51.0 million development and $150.0 million commercial) related to recent asset acquisitions.